BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16621038)

  • 1. Ribonucleotide reductase inhibitors as anti-herpes agents.
    Wnuk SF; Robins MJ
    Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo.
    Liuzzi M; Déziel R; Moss N; Beaulieu P; Bonneau AM; Bousquet C; Chafouleas JG; Garneau M; Jaramillo J; Krogsrud RL
    Nature; 1994 Dec; 372(6507):695-8. PubMed ID: 7990963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
    Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
    Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
    Field HJ; Biswas S
    Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
    Tsimberidou AM; Alvarado Y; Giles FJ
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro sensitivity of clinical isolates and drug-resistant mutants of herpes simplex virus against seven antiviral drugs.
    Salmerón F; Hernáez R; Rodríguez C
    J Chemother; 1989 Jul; 1(4 Suppl):1110-2. PubMed ID: 16312794
    [No Abstract]   [Full Text] [Related]  

  • 8. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents.
    Moss N; Beaulieu P; Duceppe JS; Ferland JM; Gauthier J; Ghiro E; Goulet S; Grenier L; Llinas-Brunet M; Plante R
    J Med Chem; 1995 Sep; 38(18):3617-23. PubMed ID: 7658449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antiviral activity of phthiobuzone analogues.
    Yang YJ; Zhao JH; Pan XD; Zhang PC
    Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):208-11. PubMed ID: 20118580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of some acylphosphonate thiosemicarbazones and evaluation of their antiviral activity.
    Breuer E; Karaman R; Zaher H; Katz E
    Drug Des Discov; 1994 Jan; 11(1):39-46. PubMed ID: 8068818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatin-β-thiosemicarbazones as potent herpes simplex virus inhibitors.
    Kang IJ; Wang LW; Hsu TA; Yueh A; Lee CC; Lee YC; Lee CY; Chao YS; Shih SR; Chern JH
    Bioorg Med Chem Lett; 2011 Apr; 21(7):1948-52. PubMed ID: 21356589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
    Krishnan K; Prathiba K; Jayaprakash V; Basu A; Mishra N; Zhou B; Hu S; Yen Y
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6248-50. PubMed ID: 18976907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
    Yu Y; Kalinowski DS; Kovacevic Z; Siafakas AR; Jansson PJ; Stefani C; Lovejoy DB; Sharpe PC; Bernhardt PV; Richardson DR
    J Med Chem; 2009 Sep; 52(17):5271-94. PubMed ID: 19601577
    [No Abstract]   [Full Text] [Related]  

  • 14. A new era for ribonucleoside reductase inhibition.
    Giles FJ
    Leuk Res; 2007 Sep; 31(9):1163-4. PubMed ID: 17416414
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
    Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
    Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-nucleoside inhibitors of herpesviruses.
    Wathen MW
    Rev Med Virol; 2002; 12(3):167-78. PubMed ID: 11987142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity.
    Moss N; Beaulieu P; Duceppe JS; Ferland JM; Garneau M; Gauthier J; Ghiro E; Goulet S; Guse I; Jaramillo J; Llinas-Brunet M; Malenfant E; Plante R; Poirier M; Soucy F; Wernic D; Yoakim C; Déziel R
    J Med Chem; 1996 Oct; 39(21):4173-80. PubMed ID: 8863795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
    Cerqueira NM; Fernandes PA; Ramos MJ
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):11-29. PubMed ID: 18221051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2.
    Sadowski LA; Upadhyay R; Greeley ZW; Margulies BJ
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34202050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 in vitro.
    Nolkemper S; Reichling J; Stintzing FC; Carle R; Schnitzler P
    Planta Med; 2006 Dec; 72(15):1378-82. PubMed ID: 17091431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.